Keyphrases
Myopic Choroidal Neovascularization (mCNV)
100%
Tissue Inhibitor of metalloproteinase-1 (TIMP-1)
100%
Geographic Atrophy
100%
Neovascular Age-related Macular Degeneration (nAMD)
60%
Age-related Macular Degeneration
60%
Healthy Controls
40%
Matrix metalloproteinase-9 (MMP-9)
40%
TIMP3
40%
Clinical Manifestations
20%
Matrix Metalloproteinases
20%
Age-related Changes
20%
Spearman's rho
20%
Plasma Concentration
20%
Commercial Immunoassays
20%
Blood Plasma
20%
Plasma Parameters
20%
Bruch's Membrane
20%
Homeostasis
20%
Extracellular Matrix
20%
Matrix metalloproteinase-2 (MMP-2)
20%
Medicine and Dentistry
Geographic Atrophy
100%
Choroidal Neovascularization
100%
Metalloprotease Inhibitor
100%
Tissue Inhibitor of Metalloproteinase 1
60%
Age Related Macular Degeneration
60%
Wet Macular Degeneration
60%
Gelatinase B
40%
Blood Plasma
20%
Gelatinase A
20%
Immunity
20%
Bruch's Membrane
20%
Homeostasis
20%
Extracellular Matrix
20%
Matrix Metalloproteinase
20%
Disease
20%
Immunoassay
20%
Nursing and Health Professions
Tissue Inhibitor of Metalloproteinase
100%
Subretinal Neovascularization
100%
Tissue Inhibitor of Metalloproteinase 1
60%
Age Related Macular Degeneration
60%
Wet Macular Degeneration
60%
Gelatinase B
40%
Blood Level
40%
Immunoassay
20%
Matrix Metalloproteinase
20%
Gelatinase A
20%
Immunology and Microbiology
Subretinal Neovascularization
100%
Blood Level
100%
Extracellular Matrix
50%
Homeostasis
50%
Immunity
50%
Bruch's Membrane
50%
Immunoassay
50%
Blood Plasma
50%
Neuroscience
Choroidal Neovascularization
100%
Metalloprotease Inhibitor
100%
Age-Related Macular Degeneration
75%
Blood Plasma
37%
MMP9
25%
Stromelysin
25%
Bruch's Membrane
12%
MMP2
12%
Immunoassay
12%
Matrix Metalloproteinase
12%
Extracellular Matrix
12%
Pharmacology, Toxicology and Pharmaceutical Science
Tissue Inhibitor of Metalloproteinase 3
40%